m8 Pharmaceuticals (formerly moksha8) has entered into an exclusive promotion and distribution agreement with Janssen Cilag S.A de C.V., whereby m8 will have the rights to commercialize and promote a portfolio of selected central nervous system (CNS) brands in the Mexican market. The main goal of this strategic partnership is to create broader access to medically established brands amongst more patients, provide continued support to physicians and strengthen treatment options in Mexico.

The portfolio includes market leading established brands, indicated for the treatment of various diseases of the central nervous system. The marketing of the products by m8 commences in September of 2020.

The strong and diverse portfolio includes: CONCERTA®, HALDOL®, HALDOL® DECANOAS, REMINYL®, SIBELIUM®, RISPERDAL®, RISPERDAL CONSTA® and TOPAMAX®.

According to IQVIA, the market size of Latin America's pharmaceutical industry is projected to grow from $55 billion in 2018 to $76 billion in 2023 with a Compound Annual Growth Rate of 7%. Brazil and Mexico are the two largest countries in Latin America, accounting for 63% of the region's pharmaceutical market, and reaching a +10.3% and 7.3% respectively growth rate from 2019 to 2020 Q1. Also worthy of mention is that CNS products occupy a considerable portion of the pharmaceutical market in Latin America, accounting for $5.3 billion in 2019.

This strategic partnership reinforces m8 Pharmaceuticals position as a market leader in the CNS space in Latin America, continuing to work together with its network of global strategic partners to bring innovative treatments and greater access to patients in the region.

"We are committed to serving patients and doctors by supporting greater access to well-established market-leading brands in the Mexican market" said Joel Barlan, m8's CEO.

Joel Barlan Chief Executive Officer T: +52 (55) 4431 2933 us.wm@moksha8.com

Rafael Ferrer Vice President of Corporate Development T: +1 (305) 299 6998 rafael.ferrer@moksha8.com